The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Coding Question: Level 3 Established Patient Evaluation and Management Office Visit

Rheumatology Coding Question: Level 3 Established Patient Evaluation and Management Office Visit

August 10, 2016 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Level 3 Established Patient E&M Visit

A 43-year-old patient is seen in the office for a follow-up visit of her RF-positive rheumatoid arthritis and primary osteoarthritis of the left knee. The patient is on sulindac, methotrexate and folic acid. At her last visit, the patient’s methotrexate dose was increased, which has greatly reduced her pain. Her pain is at Level 2 for her knees, and her wrists are at Level 1. The osteoarthritis is stable. The patient denies any chest pain; her dyspnea and all other systems are negative. She does not smoke, and her family has no history of any rheumatic diseases.

You Might Also Like
  • Rheumatology Coding Answer: Level 3 Established Patient Evaluation and Management Office Visit
  • Rheumatology Coding Corner Question: Established Patient Office Visit with Acute Gout
  • Rheumatology Coding Question: Deconstructing Evaluation and Management Codes
Explore This Issue
August 2016
Also By This Author
  • Hardship Exception Applications Open for Clinicians Struggling with Quality Payment Program Reporting in 2020

On examination, the patient is alert and oriented. Her weight is 155 lbs., height 5 feet and 6 inches with a temperature of 98ºF. There is no lymphadenopathy. Her lungs are clear. She has a regular heart rate and rhythm with no murmurs or friction rubs. Her skin shows no lesions or rashes, and her abdomen is soft with no masses or HSM.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Musculoskeletal exam: Bony proliferation and slight ulnar deviation in the bilateral wrists, bony proliferation and slightly decreased flexion in the bilateral second and fifth PIP joints, and bony proliferation of the bilateral knees. All other joints are unremarkable with FROM.

Diagnoses:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Rheumatoid arthritis with rheumatoid factor;
  2. Osteoarthritis of the left knee;
  3. Long-term nonsteroidal anti-inflammatory drug (NSAID); and
  4. Long-term disease-modifying anti-rheumatic drug (DMARD).

Plan: Complete blood count and liver function tests are ordered to monitor drug toxicity. The patient is to continue on her current medication regimen. The patient is told to schedule a follow-up visit in two months.

How is this coded?

Filed Under: Billing/Coding, From the College, Practice Management Tagged With: Billing, Coding, Evaluation, Management, office, patient care, Practice Management, rheumatologist, rheumatology, visitIssue: August 2016

You Might Also Like:
  • Rheumatology Coding Answer: Level 3 Established Patient Evaluation and Management Office Visit
  • Rheumatology Coding Corner Question: Established Patient Office Visit with Acute Gout
  • Rheumatology Coding Question: Deconstructing Evaluation and Management Codes
  • Rheumatology Coding Corner Answer: Established Patient Office Visit with Acute Gout

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)